Patients with established atherosclerotic cardiovascular disease (ASCVD) need long-term
antiplatelet therapy to decrease the risk of future ASCVD events. We searched PubMed …

Aim To compare the efficacy and safety of P2Y12 inhibitor or aspirin monotherapy for
secondary prevention in patients with atherosclerotic cardiovascular disease (ASCVD) …

Background Antiplatelet therapy is recommended among patients with established
atherosclerosis. We compared monotherapy with a P2Y 12 inhibitor versus aspirin for …

Aspirin remains the single most widely used antithrombotic treatment for long-term
secondary prevention of cardiovascular (CV) disease, including coronary artery disease …

Background Aspirin is the only antiplatelet agent with a Class I recommendation for long-
term prevention of cardiovascular events in patients with coronary artery disease (CAD) …

Background The ADAPTABLE (Aspirin Dosing: A Patient‐Centric Trial Assessing Benefits
and Long‐Term Effectiveness) was a large, pragmatic, randomized controlled trial that found …

Current European and American guidelines for the management of patients with coronary
artery disease (CAD) identify aspirin as a fundamental treatment for the secondary …

Introduction Although the role of aspirin for primary prevention of atherosclerotic
cardiovascular disease (ASCVD) has been disputed, its use in secondary ASCVD …

Aspirin represents the sine qua non for antiplatelet pharmacotherapy in patients with
cardiovascular diseases because of its well-established role in secondary prevention and its …

Aspirin's antithrombotic effects have a long-established place in the prevention of
cardiovascular disease (CVD), and its traditional use as a core therapy for secondary …